Serum Institute of India is the vaccine producer that will invest 50 million pounds ($68.24 million) in Oxford Biomedica, one of the COVID-19 vaccine manufacturers for drug major AstraZeneca, the British cell therapy firm said.
- Anthropic IPO at $1.5 Trillion: What It Means for Indian Stock Markets and AI Investors
- Ashoka Buildcon Loses Rs 846 Crore Saudi Arabia ContractΒ
- South Korea Becomes Fourth Country to Cross $1 Trillion in ExportsΒ
- Humyn Labs Raises $47 Million in Series A Funding
- ArMee Infotech Signs Rs 1,629 Cr Solar MoU With MSEDCL
The proceeds of the transaction will be used to fund the development of the fallow area at Oxbox, the group’s 84,000 sq. ft manufacturing facility based in Oxford, UK, into a flexible advanced manufacturing space and the validation of several independent cGMP suites, expected to come online in mid-2023.
Live
